2756257-56-2
Chemical Structure
SS-3091
- CAS. Nr.: 2756257-56-2
- Formula:C36H34F3N5O
- Molecular Weight:609.68
IUPAC Name: N-(3-(2-((3,5-dimethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)-8-methylquinazolin-6-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide
InChIKey: IFFNKLNLKZXFFI-UHFFFAOYSA-N
SMILES: O=C(C1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(C)C(C3=CC4=C(C(C)=C3)N=C(NC5=CC=C6C(C(CN(CC6)C)C)=C5)N=C4)=C2
Biological Activity: SS-3091 is a pan-KRas inhibitor active across KRasG12D, KRasG12C, KRasG12V, KRasG12S mutants, with minimal effects on non-KRas-driven cancer cells. SS-3091 binds to the KRas·ARaf interaction interface, destabilizes the complex, and attenuates KRas activity. SS-3091 suppresses phosphorylation of S6K, Akt, and ERK. SS-3091 reduces proliferation and decreases colony formation of cancer cells bearing KRasG12 mutations. SS-3091 can be used for the research of KRas-driven cancers[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SS-3091 | SS-3091 is a pan-KRas inhibitor active across KRasG12D, KRasG12C, KRasG12V, KRasG12S mutants, with minimal effects on non-KRas-driven cancer cells. SS-3091 binds to the KRas·ARaf interaction interface, destabilizes the complex, and attenuates KRas activity. SS-3091 suppresses phosphorylation of S6K, Akt, and ERK. SS-3091 reduces proliferation and decreases colony formation of cancer cells bearing KRasG12 mutations. SS-3091 can be used for the research of KRas-driven cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
